Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Cytomegalovirus viremia associated with increased mortality in cryptococcal meningitis in sub-Saharan Africa.

Skipper CP, Schleiss MR, Bangdiwala AS, Hernandez-Alvarado N, Taseera K, Nabeta HW, Musubire AK, Lofgren SM, Wiesner DL, Rhein J, Rajasingham R, Schutz C, Meintjes G, Muzoora C, Meya DB, Boulware DR; COAT Team.

Clin Infect Dis. 2019 Sep 1. pii: ciz864. doi: 10.1093/cid/ciz864. [Epub ahead of print]

PMID:
31504335
2.

Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.

Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, Kiggundu R, Pastick KA, Ssebambulidde K, Akampurira A, Williams DA, Bangdiwala AS, Abassi M, Musubire AK, Nicol MR, Muzoora C, Meya DB, Boulware DR; ASTRO-CM team.

Lancet Infect Dis. 2019 Aug;19(8):843-851. doi: 10.1016/S1473-3099(19)30127-6.

PMID:
31345462
3.

Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations.

Bongomin F, Govender NP, Chakrabarti A, Robert-Gangneux F, Boulware DR, Zafar A, Oladele RO, Richardson MD, Gangneux JP, Alastruey-Izquierdo A, Bazira J, Boyles TH, Sarcarlal J, Nacher M, Obayashi T, Worodria W, Pasqualotto AC, Meya DB, Cheng B, Sriruttan C, Muzoora C, Kambugu A, Rodriguez Tudela JL, Jordan A, Chiller TM, Denning DW.

Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1581-1584. doi: 10.1007/s10096-019-03600-4. No abstract available.

PMID:
31175479
4.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study.

Ponatshego PL, Lawrence DS, Youssouf N, Molloy SF, Alufandika M, Bango F, Boulware DR, Chawinga C, Dziwani E, Gondwe E, Hlupeni A, Hosseinipour MC, Kanyama C, Meya DB, Mosepele M, Muthoga C, Muzoora CK, Mwandumba H, Ndhlovu CE, Rajasingham R, Sayed S, Shamu S, Tsholo K, Tugume L, Williams D, Maheswaran H, Shiri T, Boyer-Chammard T, Loyse A, Chen T, Wang D, Lortholary O, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN, Niessen LW.

BMJ Open. 2019 Apr 1;9(4):e026288. doi: 10.1136/bmjopen-2018-026288.

5.

The Mouse Inhalation Model of Cryptococcus neoformans Infection Recapitulates Strain Virulence in Humans and Shows that Closely Related Strains Can Possess Differential Virulence.

Mukaremera L, McDonald TR, Nielsen JN, Molenaar CJ, Akampurira A, Schutz C, Taseera K, Muzoora C, Meintjes G, Meya DB, Boulware DR, Nielsen K.

Infect Immun. 2019 Apr 23;87(5). pii: e00046-19. doi: 10.1128/IAI.00046-19. Print 2019 Mar.

6.

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2019 Jan 14;20(1):48. doi: 10.1186/s13063-018-3155-9.

7.

Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality.

Musubire AK, Meya DB, Rhein J, Meintjes G, Bohjanen PR, Nuwagira E, Muzoora C, Boulware DR, Hullsiek KH; COAT and ASTRO trial teams.

PLoS One. 2018 Dec 31;13(12):e0209337. doi: 10.1371/journal.pone.0209337. eCollection 2018.

8.

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.

Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, Boyer-Chammard T, Chen T, Dromer F, Hlupeni A, Hope W, Hosseinipour MC, Kanyama C, Lortholary O, Loyse A, Meya DB, Mosepele M, Muzoora C, Mwandumba HC, Ndhlovu CE, Niessen L, Schutz C, Stott KE, Wang D, Lalloo DG, Meintjes G, Jaffar S, Harrison TS, Jarvis JN.

Trials. 2018 Nov 23;19(1):649. doi: 10.1186/s13063-018-3026-4. Erratum in: Trials. 2019 Jan 14;20(1):48.

9.

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.

Loyse A, Burry J, Cohn J, Ford N, Chiller T, Ribeiro I, Koulla-Shiro S, Mghamba J, Ramadhani A, Nyirenda R, Aliyu SH, Wilson D, Le T, Oladele R, Lesikari S, Muzoora C, Kalata N, Temfack E, Mapoure Y, Sini V, Chanda D, Shimwela M, Lakhi S, Ngoma J, Gondwe-Chunda L, Perfect C, Shroufi A, Andrieux-Meyer I, Chan A, Schutz C, Hosseinipour M, Van der Horst C, Klausner JD, Boulware DR, Heyderman R, Lalloo D, Day J, Jarvis JN, Rodrigues M, Jaffar S, Denning D, Migone C, Doherty M, Lortholary O, Dromer F, Stack M, Molloy SF, Bicanic T, van Oosterhout J, Mwaba P, Kanyama C, Kouanfack C, Mfinanga S, Govender N, Harrison TS.

Lancet Infect Dis. 2019 Apr;19(4):e143-e147. doi: 10.1016/S1473-3099(18)30493-6. Epub 2018 Oct 18. Review.

PMID:
30344084
10.

HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts.

Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, Schutz C, Taseera K, Williams DA, Abassi M, Muzoora C, Musubire AK, Meintjes G, Meya DB, Boulware DR; COAT and ASTRO-CM teams .

J Infect Dis. 2019 Feb 23;219(6):877-883. doi: 10.1093/infdis/jiy602.

PMID:
30325463
11.

Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity.

Kinloch NN, Lee GQ, Carlson JM, Jin SW, Brumme CJ, Byakwaga H, Muzoora C, Bwana MB, Cobarrubias KD, Hunt PW, Martin JN, Carrington M, Bangsberg DR, Harrigan PR, Brockman MA, Brumme ZL.

J Virol. 2018 Dec 10;93(1). pii: e01502-18. doi: 10.1128/JVI.01502-18. Print 2019 Jan 1.

12.

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Ssebambulidde K, Bangdiwala AS, Kwizera R, Kandole TK, Tugume L, Kiggundu R, Mpoza E, Nuwagira E, Williams DA, Lofgren SM, Abassi M, Musubire AK, Cresswell FV, Rhein J, Muzoora C, Hullsiek KH, Boulware DR, Meya DB; Adjunctive Sertraline for Treatment of HIV-associated Cryptococcal Meningitis Team .

Clin Infect Dis. 2019 May 30;68(12):2094-2098. doi: 10.1093/cid/ciy817.

13.

High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study).

Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, Tugume L, Muzoora C, Lukande R, Lamorde M, Aarnoutse R, Meya D, Boulware DR, Elliott AM.

Wellcome Open Res. 2018 Jul 10;3:83. doi: 10.12688/wellcomeopenres.14691.1. eCollection 2018.

14.

Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation.

Rhein J, Hullsiek KH, Evans EE, Tugume L, Nuwagira E, Ssebambulidde K, Kiggundu R, Mpoza E, Musubire AK, Bangdiwala AS, Bahr NC, Williams DA, Abassi M, Muzoora C, Meya DB, Boulware DR; ASTRO-CM study team .

Open Forum Infect Dis. 2018 May 24;5(8):ofy122. doi: 10.1093/ofid/ofy122. eCollection 2018 Aug.

15.

Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda.

Cresswell FV, Bangdiwala AS, Bahr NC, Trautner E, Nuwagira E, Ellis J, Rajasingham R, Rhein J, Williams DA, Muzoora C, Elliott AM, Meya DB, Boulware DR.

Wellcome Open Res. 2018 May 29;3:64. doi: 10.12688/wellcomeopenres.14610.2. eCollection 2018.

16.

Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.

McCluskey SM, Lee GQ, Kamelian K, Kembabazi A, Musinguzi N, Bwana MB, Muzoora C, Haberer JE, Hunt PW, Martin JN, Boum Y 2nd, Bangsberg DR, Harrigan PR, Siedner MJ.

AIDS Patient Care STDS. 2018 Jul;32(7):257-264. doi: 10.1089/apc.2018.0020.

17.

Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara Regional Referral Hospital, southwestern Uganda.

Katemba C, Muzoora C, Muwanguzi E, Mwambi B, Atuhairwe C, Taremwa IM.

J Blood Med. 2018 Jun 27;9:105-110. doi: 10.2147/JBM.S157148. eCollection 2018.

18.

CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.

Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y 2nd, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.

19.

Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.

Chang JL, Tsai AC, Musinguzi N, Haberer JE, Boum Y, Muzoora C, Bwana M, Martin JN, Hunt PW, Bangsberg DR, Siedner MJ.

Ann Intern Med. 2018 Aug 7;169(3):146-155. doi: 10.7326/M17-2252. Epub 2018 Jun 26.

20.

Evaluation of a point-of-care immunoassay test kit 'StrongStep' for cryptococcal antigen detection.

Mpoza E, Mukaremera L, Kundura DA, Akampurira A, Luggya T, Tadeo KK, Pastick KA, Bridge SC, Tugume L, Kiggundu R, Musubire AK, Williams DA, Muzoora C, Nalintya E, Rajasingham R, Rhein J, Boulware DR, Meya DB, Abassi M.

PLoS One. 2018 Jan 5;13(1):e0190652. doi: 10.1371/journal.pone.0190652. eCollection 2018.

21.

Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.

Bahr NC, Nuwagira E, Evans EE, Cresswell FV, Bystrom PV, Byamukama A, Bridge SC, Bangdiwala AS, Meya DB, Denkinger CM, Muzoora C, Boulware DR; ASTRO-CM Trial Team.

Lancet Infect Dis. 2018 Jan;18(1):68-75. doi: 10.1016/S1473-3099(17)30474-7. Epub 2017 Sep 14.

22.

Prevalence and clinical impacts of HIV-1 intersubtype recombinants in Uganda revealed by near-full-genome population and deep sequencing approaches.

Lee GQ, Bangsberg DR, Mo T, Lachowski C, Brumme CJ, Zhang W, Lima VD, Boum Y 2nd, Mwebesa BB, Muzoora C, Andia I, Mbalibulha Y, Kembabazi A, Carroll R, Siedner MJ, Haberer JE, Mocello AR, Kigozi SH, Hunt PW, Martin JN, Harrigan PR.

AIDS. 2017 Nov 13;31(17):2345-2354. doi: 10.1097/QAD.0000000000001619.

23.

Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis.

Schutz C, Boulware DR, Huppler-Hullsiek K, von Hohenberg M, Rhein J, Taseera K, Thienemann F, Muzoora C, Meya DB, Meintjes G.

Open Forum Infect Dis. 2017 Jun 20;4(3):ofx127. doi: 10.1093/ofid/ofx127. eCollection 2017 Summer.

24.

Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016.

Flynn AG, Meya DB, Hullsiek KH, Rhein J, Williams DA, Musubire A, Morawski BM, Taseera K, Sadiq A, Ndyatunga L, Roediger M, Rajasingham R, Bohjanen PR, Muzoora C, Boulware DR.

Open Forum Infect Dis. 2017 Apr 19;4(2):ofx077. doi: 10.1093/ofid/ofx077. eCollection 2017 Spring.

25.

Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.

Lofgren S, Hullsiek KH, Morawski BM, Nabeta HW, Kiggundu R, Taseera K, Musubire A, Schutz C, Abassi M, Bahr NC, Tugume L, Muzoora C, Williams DA, Rolfes MA, Velamakanni SS, Rajasingham R, Meintjes G, Rhein J, Meya DB, Boulware DR; COAT and ASTRO-CM Trial Teams.

J Infect Dis. 2017 Mar 1;215(5):693-697. doi: 10.1093/infdis/jix033.

26.

Real-time electronic adherence monitoring plus follow-up improves adherence compared with standard electronic adherence monitoring.

Haberer JE, Musinguzi N, Tsai AC, Boum Y 2nd, Bwana BM, Muzoora C, Hunt PW, Martin JN, Bangsberg DR.

AIDS. 2017 Jan 2;31(1):169-171.

27.

Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

Tugume L, Morawski BM, Abassi M, Bahr NC, Kiggundu R, Nabeta HW, Hullsiek KH, Taseera K, Musubire AK, Schutz C, Muzoora C, Williams DA, Rolfes MA, Meintjes G, Rhein J, Meya DB, Boulware DR.

HIV Med. 2017 Jan;18(1):13-20. doi: 10.1111/hiv.12387. Epub 2016 Apr 28.

28.

Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda.

Lee GQ, Lachowski C, Cai E, Lima VD, Boum Y, Muzoora C, Mocello AR, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR.

AIDS. 2016 Jul 17;30(11):1781-8. doi: 10.1097/QAD.0000000000001128.

29.

Upper gastrointestinal diseases in patients for endoscopy in South-Western Uganda.

Obayo S, Muzoora C, Ocama P, Cooney MM, Wilson T, Probert CS.

Afr Health Sci. 2015 Sep;15(3):959-66. doi: 10.4314/ahs.v15i3.33.

30.

Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding.

Boulware DR, von Hohenberg M, Rolfes MA, Bahr NC, Rhein J, Akampurira A, Williams DA, Taseera K, Schutz C, McDonald T, Muzoora C, Meintjes G, Meya DB, Nielsen K, Huppler Hullsiek K.

Open Forum Infect Dis. 2015 Dec 12;3(1):ofv194. doi: 10.1093/ofid/ofv194. eCollection 2016 Jan.

31.

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis.

Rolfes MA, Rhein J, Schutz C, Taseera K, Nabeta HW, Huppler Hullsiek K, Akampuira A, Rajasingham R, Musubire A, Williams DA, Thienemann F, Bohjanen PR, Muzoora C, Meintjes G, Meya DB, Boulware DR.

Open Forum Infect Dis. 2015 Dec 28;2(4):ofv157. doi: 10.1093/ofid/ofv157. eCollection 2015 Dec.

32.

High Prevalence of Metabolic Syndrome and Cardiovascular Disease Risk Among People with HIV on Stable ART in Southwestern Uganda.

Muyanja D, Muzoora C, Muyingo A, Muyindike W, Siedner MJ.

AIDS Patient Care STDS. 2016 Jan;30(1):4-10. doi: 10.1089/apc.2015.0213. Epub 2015 Dec 18.

33.

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7224-31. doi: 10.1128/AAC.01698-15. Epub 2015 Sep 8.

34.

The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.

Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, Musubire A, Rajasingham R, Williams DA, Thienemann F, Muzoora C, Meintjes G, Meya DB, Boulware DR.

Clin Infect Dis. 2014 Dec 1;59(11):1607-14. doi: 10.1093/cid/ciu596. Epub 2014 Jul 23. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1449.

35.

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.

Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G; COAT Trial Team.

N Engl J Med. 2014 Jun 26;370(26):2487-98. doi: 10.1056/NEJMoa1312884.

36.

Prevalence and virologic consequences of transmitted HIV-1 drug resistance in Uganda.

Lee GQ, Bangsberg DR, Muzoora C, Boum Y, Oyugi JH, Emenyonu N, Bennett J, Hunt PW, Knapp D, Brumme CJ, Harrigan PR, Martin JN.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):896-906. doi: 10.1089/AID.2014.0043. Epub 2014 Jul 29.

37.

Bedside measures of malnutrition and association with mortality in hospitalized adults.

Asiimwe SB, Muzoora C, Wilson LA, Moore CC.

Clin Nutr. 2015 Apr;34(2):252-6. doi: 10.1016/j.clnu.2014.03.013. Epub 2014 Apr 5.

PMID:
24755235
38.

Tobacco use among adults initiating treatment for HIV infection in rural Uganda.

Kruse GR, Bangsberg DR, Hahn JA, Haberer JE, Hunt PW, Muzoora C, Bennett JP, Martin JN, Rigotti NA.

AIDS Behav. 2014 Jul;18(7):1381-9. doi: 10.1007/s10461-014-0737-8.

39.

The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.

Byakwaga H, Boum Y 2nd, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW.

J Infect Dis. 2014 Aug 1;210(3):383-91. doi: 10.1093/infdis/jiu115. Epub 2014 Feb 28.

40.

AIDS-related mycoses: the way forward.

Brown GD, Meintjes G, Kolls JK, Gray C, Horsnell W; Working Group from the EMBO-AIDS Related Mycoses Workshop, Achan B, Alber G, Aloisi M, Armstrong-James D, Beale M, Bicanic T, Black J, Bohjanen P, Botes A, Boulware DR, Brown G, Bunjun R, Carr W, Casadevall A, Chang C, Chivero E, Corcoran C, Cross A, Dawood H, Day J, De Bernardis F, De Jager V, De Repentigny L, Denning D, Eschke M, Finkelman M, Govender N, Gow N, Graham L, Gryschek R, Hammond-Aryee K, Harrison T, Heard N, Hill M, Hoving JC, Janoff E, Jarvis J, Kayuni S, King K, Kolls J, Kullberg BJ, Lalloo DG, Letang E, Levitz S, Limper A, Longley N, Machiridza TR, Mahabeer Y, Martinsons N, Meiring S, Meya D, Miller R, Molloy S, Morris L, Mukaremera L, Musubire AK, Muzoora C, Nair A, Nakiwala Kimbowa J, Netea M, Nielsen K, O'hern J, Okurut S, Parker A, Patterson T, Pennap G, Perfect J, Prinsloo C, Rhein J, Rolfes MA, Samuel C, Schutz C, Scriven J, Sebolai OM, Sojane K, Sriruttan C, Stead D, Steyn A, Thawer NK, Thienemann F, Von Hohenberg M, Vreulink JM, Wessels J, Wood K, Yang YL.

Trends Microbiol. 2014 Mar;22(3):107-9. doi: 10.1016/j.tim.2013.12.008.

41.

The dynamic relationship between social support and HIV-related stigma in rural Uganda.

Takada S, Weiser SD, Kumbakumba E, Muzoora C, Martin JN, Hunt PW, Haberer JE, Kawuma A, Bangsberg DR, Tsai AC.

Ann Behav Med. 2014 Aug;48(1):26-37. doi: 10.1007/s12160-013-9576-5.

42.

Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast.

Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, Schutz C, Kwizera R, Butler EK, Meintjes G, Muzoora C, Bischof JC, Meya DB.

Emerg Infect Dis. 2014 Jan;20(1):45-53. doi: 10.3201/eid2001.130906.

43.

Treatment as long-term prevention: sustained reduction in HIV sexual transmission risk with use of antiretroviral therapy in rural Uganda.

Siedner MJ, Musinguzi N, Tsai AC, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Hunt PW, Martin JN, Haberer JE, Bangsberg DR.

AIDS. 2014 Jan 14;28(2):267-71. doi: 10.1097/QAD.0000000000000136.

44.

Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV.

Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):551-6. doi: 10.1097/QAI.0000000000000085.

45.

Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, Muzoora C, Phulusa J, Taseera K, Kanyembe C, Wilson D, Hosseinipour MC, Brouwer AE, Limmathurotsakul D, White N, van der Horst C, Wood R, Meintjes G, Bradley J, Jaffar S, Harrison T.

Clin Infect Dis. 2014 Mar;58(5):736-45. doi: 10.1093/cid/cit794. Epub 2013 Dec 6.

46.

Reversal of the Kynurenine pathway of tryptophan catabolism may improve depression in ART-treated HIV-infected Ugandans.

Martinez P, Tsai AC, Muzoora C, Kembabazi A, Weiser SD, Huang Y, Haberer JE, Martin JN, Bangsberg DR, Hunt PW.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):456-62. doi: 10.1097/QAI.0000000000000062.

47.

HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods.

Matthews LT, Kaida A, Kanters S, Byakwagamd H, Mocello AR, Muzoora C, Kembabazi A, Haberer JE, Martin JN, Bangsberg DR, Hunt PW.

AIDS. 2013 Oct;27 Suppl 1:S105-12. doi: 10.1097/QAD.0000000000000040.

48.

Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.

Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR.

Clin Infect Dis. 2014 Jan;58(1):113-6. doi: 10.1093/cid/cit641. Epub 2013 Sep 24.

49.

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes.

Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzi P, Omarjee S, Martin E, Lee GQ, Baraki B, Danroth R, McCloskey R, Muzoora C, Bangsberg DR, Hunt PW, Goulder PJ, Walker BD, Harrigan PR, Martin JN, Ndung'u T, Brockman MA, Brumme ZL.

Retrovirology. 2013 Sep 16;10:100. doi: 10.1186/1742-4690-10-100.

50.

Disinhibition in risky sexual behavior in men, but not women, during four years of antiretroviral therapy in rural, southwestern Uganda.

Kembabazi A, Bajunirwe F, Hunt PW, Martin JN, Muzoora C, Haberer JE, Bangsberg DR, Siedner MJ.

PLoS One. 2013 Jul 19;8(7):e69634. doi: 10.1371/journal.pone.0069634. Print 2013.

Supplemental Content

Loading ...
Support Center